ANDA User Fees: Negotiators Close To Agreement, But Backlog Is Sticking Point

The generics industry does not appear satisfied with an FDA proposal to treat all applications equally under a new generic drug user fee program, preferring instead to create another, separate user fee that would clear the ANDA application backlog faster.